ArticleJournal of thrombosis and haemostasis : JTH2022
Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease.
Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Efficacy of desmopressin in reducing post-procedural bleeding among chronic kidney disease patients: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Sex differences in long-term outcomes by platelet reactivity in patients with chronic kidney disease.Heart and vessels · 2026Article
- Inflammation and Dysregulated Bone Turnover Confound Serum ICAM-1 as a Cardiovascular Marker in Hemodialysis.Biomolecules · 2026Article
- Molecular biomarkers in dialysis-related thrombosis and anticoagulation monitoring: thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, soluble thrombomodulin, tPA/PAI-1/tPAIC, and Anti-Xa.Frontiers in medicine · 2026Review
- Association between hemoglobin-to-creatinine ratio and all-cause mortality in patients with coronary artery disease.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Article
- Machine learning model predicts clotting risk during CRRT in ESKD patients: a SHAP-interpretable approach.Renal failure · 2025Article
- Redefining haemostasis: Role of rotational thromboelastometry in critical care settings.World journal of critical care medicine · 2025Review
- Oxidative Score and Microvesicle Profile Suggest Cardiovascular Risk in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2025Article
- Platelet count has a nonlinear association with 30-day in-hospital mortality in ICU end-stage kidney disease patients: a multicenter retrospective cohort study.Scientific reports · 2024Article
- Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients.International journal of molecular sciences · 2024Review
- Concerns about the application of resistance exercise with blood-flow restriction and thrombosis risk in hemodialysis patients.Journal of sport and health science · 2024Article
- Spontaneous bleeding in chronic kidney disease: global coagulation assays may predict bleeding risk.Research and practice in thrombosis and haemostasis · 2024Article
- COVID-19 increases extracorporeal coagulation during hemodialysis associated with upregulation of vWF/FBLN5 signaling in patients with severe/critical symptoms.BMC infectious diseases · 2024Article
- Thrombectomy versus combined thrombolysis and thrombectomy in patients with large vessel occlusion and chronic kidney disease.Heliyon · 2024Article
- Development and Validation of a Risk-Prediction Nomogram for Preoperative Blood Type and Antibody Testing in Spinal Fusion Surgery.Orthopaedic surgery · 2024Article
- Association between systemic inflammatory indicators with the survival of chronic kidney disease: a prospective study based on NHANES.Frontiers in immunology · 2024Article
- Consumptive coagulopathy in the ICU.Hematology. American Society of Hematology. Education Program · 2023Review
- Risk and factors associated with venous thromboembolism following abdominal transplantation.Surgery open science · 2023Article
- Molecular mechanism ofAmerican journal of translational research · 2023Article
- Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin.Journal of clinical medicine · 2022Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemostasis evaluation in chronic kidney disease (CKD) is critical for optimal management of thrombotic and bleeding events. Standard coagulation screens are inadequate for predicting coagulopathy in CKD.
objectiveTo evaluate hemostasis parameters in patients with different stages of CKD using novel coagulation assays. PATIENTS/
methodsCross-sectional study of 30 healthy controls (HC) and 120 CKD patients (10 Stage 2, 20 Stage 3, 20 Stage 4, 20 Stage 5 not requiring renal replacement therapy, 20 transplant, 10 newly started on hemodialysis [HD], 20 established on HD). Standard laboratory tests were performed in addition to rotational thromboelastometry (ROTEM), multiple electrode aggregometry (MEA), thrombin generation assays, D-dimer, and markers of thrombogenesis (thrombin-antithrombin [TAT]), fibrinolysis, and endothelial activation (intercellular adhesion molecule-1 [ICAM-1]).
resultsD-dimer, TAT, and ICAM-1 concentrations were significantly higher in patients with CKD than HC (P < .01). ROTEM maximum clot firmness was significantly higher in patients than in HC (P < .01). In CKD Stage 5 patients (pre-HD and started HD) adenosine diphosphate and thrombin receptor activating peptide MEA tests were significantly lower than HC indicating platelet aggregation defect (P < .05). Multivariate analysis confirmed the direct effect of estimated glomerular filtration rate (eGFR) in the variance of ROTEM and MEA tests. Endogenous thrombin potential and peak thrombin were not statistically different between groups, but Stage 5 CKD patients had prolonged lag time (7.91 vs. 6.33, P < .001) and time to thrombin peak (10.8 vs. 9.5, P < .05) compared to HC.
conclusionsPatients with CKD exhibit features of concomitant hypercoagulability measured by ROTEM and platelet dysfunction measured with MEA. eGFR was an independent determinant of platelet dysfunction and hypercoagulability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.